10-Q: Stemtech Corp. Q3 2026: Revenue Plummets Amidst Financial Strain

Stemtech Corporation reported a sharp decline in net sales for Q3 2026, primarily due to a reduced distributor base, alongside continued net losses and a significant working capital deficit.

Summary

• Stemtech Corporation's Q3 2026 results show a significant decrease in net sales, falling to $282,484 from $852,300 in the same period last year, and $1,374,753 for the nine months ended September 30, 2026, down from $2,418,271 in 2025.
• The company experienced a net loss of $478,575 for the three months ended September 30, 2026, an improvement from $812,541 in the prior year, and a net loss of $1,931,993 for the nine months ended September 30, 2026, an improvement from $2,567,547 in 2025.
• Operating expenses were reduced, with total operating expenses for Q3 2026 at $584,968, down from $1,021,700 in Q3 2025, and for the nine months at $2,532,944, down from $3,799,873 in 2025.
• The company has a substantial working capital deficit of $10,663,135 as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern.
• Cash used in operating activities increased to $777,119 for the nine months ended September 30, 2026, from $610,584 in the same period of 2025.
• The company is relying on various financing activities, including convertible debt conversion, notes payable, inventory financing, and business advances, to fund operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant revenue decline, persistent net losses, and substantial working capital deficit, indicating ongoing financial challenges.

Positives

• Operating expenses were significantly reduced in both the three-month and nine-month periods of 2026 compared to 2025, reflecting cost management initiatives.
• Net loss improved in both the three-month and nine-month periods of 2026 compared to 2025, indicating a reduction in overall losses.
• The company launched the Stemtech BioSciences e-commerce retail platform in February 2026 to diversify revenue streams.
• A strategic association with Tony Little was formed in October 2026 to promote products through television and digital media, funded by a third-party investor.
• Product supply issues that affected early 2026 have been resolved, and the company had sufficient inventory for Q3 2026.

Negatives

• Net sales decreased significantly by $569,816 in Q3 2026 compared to Q3 2025, and by $1,043,518 for the nine months ended September 30, 2026, primarily due to a smaller distributor base.
• Gross margin decreased to 75.6% in Q3 2026 from 80.1% in Q3 2025, and to 75.2% for the nine months ended September 30, 2026, from 80.8% in 2025, due to fixed fulfillment and freight costs.
• The company has a substantial working capital deficit of $10,663,135 as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern.
• Cash used in operating activities increased by $166,535 for the nine months ended September 30, 2026, compared to the same period in 2025.
• The company has a significant accumulated deficit of $36,809,750 as of September 30, 2026.
• The company is heavily reliant on external financing and debt instruments to fund its operations.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenues and raise additional capital.
• The company has a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.
• Reliance on the Leviston Resources, LLC senior secured convertible facility carries risk as the lender retains full discretion over future funding.
• Additional equity or convertible debt financings may result in significant dilution to existing shareholders.
• The company is involved in ongoing litigation with a former CEO regarding unpaid salary and vacation pay, with a claim of $267,000.
• The company was in default under certain Merchant Cash Advance (MCA) financing agreements, with lenders filing legal proceedings.

Future Outlook

Management expects the Tony Little product sales program, launched in October 2026, to support sales growth and the distributor base. The company anticipates needing additional capital through equity or debt securities, factoring, and business advances to fund operations and growth initiatives. There is no assurance that such financing will be available on acceptable terms.

Management Comments

• Management is focused on rebuilding the distributor network through new distributor recruitment, re-engagement of former distributors and expanded sales programs, and expects these efforts to support sales growth in future periods.
• Management believes the association with Tony Little is a significant growth opportunity and expects it to introduce the Company's products to a large new customer audience, attract new distributors, and drive significant growth in sales volume.
• Management believes the terms of related-party transactions were reasonable given the Company's financial condition and represent the most practical sources of capital during the periods presented.

Industry Context

StockSavvy.ai notes that Stemtech operates in the stem cell nutrition and network marketing sector, a niche that has seen interest but also faces challenges related to regulatory scrutiny and direct-to-consumer sales models. The company's recent e-commerce platform launch and strategic association with Tony Little indicate an effort to adapt to evolving market dynamics and broaden customer reach beyond traditional network marketing.

Comparison to Industry Standards

• The company's revenue decline in Q3 2026 contrasts with potential growth in the broader wellness and direct-to-consumer e-commerce sectors.
• The significant net losses and working capital deficit are concerning when compared to more established companies in the health and wellness industry that typically demonstrate profitability and stronger balance sheets.
• The reliance on financing through convertible notes and business advances is common for early-stage or struggling companies but is less sustainable than revenue-driven growth seen in industry leaders.

Legal Proceedings

• A lawsuit was filed by the former CEO for unpaid salary and vacation pay totaling approximately $267,000, related to a period prior to the current management team's control. The company has filed a counterclaim and accrued $267,000 for this matter.
• The company was in default under certain Merchant Cash Advance (MCA) financing agreements, with lenders filing legal proceedings for recovery of outstanding balances.

Related Party Transactions

• As of September 30, 2026, the company had outstanding related-party convertible promissory notes payable to President and Chief Operating Officer, Mr. John W. Meyer ($171,475), and director, Mr. Darryl V. Green ($25,000).
• Short-term working capital loans totaling approximately $259,708 (including accrued interest) were outstanding from John W. Meyer, President and Chief Operating Officer, bearing 18% interest.
• Restricted shares of common stock were issued to six members of the Board of Directors and executive officers on February 20, 2026, as compensation for services.

Stakeholder Impact

• Existing shareholders face potential dilution from ongoing convertible debt conversions and future equity financings.
• Creditors and lenders may be impacted by the company's ongoing financial struggles and defaults on certain financing agreements.
• Employees and independent business partners may be affected by the company's efforts to manage costs and its reliance on external financing.

Next Steps

• Rebuild the distributor network through new distributor recruitment and re-engagement of former distributors.
• Expand sales programs to support sales growth.
• Leverage the Tony Little product sales program to drive sales volume and attract new distributors.
• Continue to raise additional capital through equity or debt securities, inventory financing, and factoring arrangements.
• Fund operations over the next twelve months through existing facilities, equity issuances, director loans, and factoring/business advances.

Key Dates

Recommendation

The filing indicates a severe decline in revenue, persistent net losses, a substantial working capital deficit, and ongoing reliance on external financing, all of which point to significant financial distress and a high risk of continued underperformance. The company's ability to continue as a going concern is in doubt.

Keywords

Stem Cell Nutrition, Network Marketing, E-commerce Platform, Distributor Sales, Financial Condition, Revenue Decline, Working Capital Deficit, Going Concern